Gershenson D M, Kavanagh J J, Copeland L J, Edwards C L, Freedman R S, Wharton J T
Cancer. 1987 Apr 1;59(7):1264-7. doi: 10.1002/1097-0142(19870401)59:7<1264::aid-cncr2820590706>3.0.co;2-o.
Fifteen patients with metastatic mixed mesodermal sarcoma of the uterus received high dose doxorubicin infusion therapy. For 12 patients, the initial dose was 90 mg/m2; the other three patients' starting doses were 50, 75, and 75 mg/m2 respectively. Twelve patients received doxorubicin as firstline chemotherapy, with a cumulative dose of 90 mg/m2 to 675 mg/m2 (median = 495 mg/m2). Three patients treated secondarily received cumulative doses of 90, 205, and 425 mg/m2. Of nine patients who had measurable disease, none had an objective response. The median survival of the 15 patients was 11.3 months, with a range of 0.5 to 51+ months. Two patients died of neutropenia related sepsis. Cardiotoxicity occurred in two patients. Eleven patients are dead of disease, and two patients are alive without evidence of disease at 49, and 51 months. Extending the doxorubicin dosage to its tolerable limits did not appear to result in improved efficacy in patients with metastatic mixed mesodermal uterine sarcomas. Future clinical trials should concentrate on doxorubicin-containing combination regimens and Phase II single agent studies.
15例子宫转移性混合性中胚层肉瘤患者接受了大剂量阿霉素输注治疗。12例患者的初始剂量为90mg/m²；另外3例患者的起始剂量分别为50、75和75mg/m²。12例患者接受阿霉素作为一线化疗，累积剂量为90mg/m²至675mg/m²（中位数=495mg/m²）。3例接受二线治疗的患者累积剂量分别为90、205和425mg/m²。9例有可测量病灶的患者中，无一例有客观反应。15例患者的中位生存期为11.3个月，范围为0.5至51+个月。2例患者死于中性粒细胞减少相关的败血症。2例出现心脏毒性。11例患者死于疾病，2例患者分别在49个月和51个月时存活且无疾病证据。将阿霉素剂量扩大到其耐受极限似乎并未提高转移性子宫混合性中胚层肉瘤患者的疗效。未来的临床试验应集中于含阿霉素的联合方案和II期单药研究。
